MONOCLONAL-ANTIBODIES TO NUCLEIC ACID-CONTAINING CELLULAR-CONSTITUENTS - PROBES FOR MOLECULAR-BIOLOGY AND AUTOIMMUNE-DISEASE

MONOCLONAL-ANTIBODIES TO NUCLEIC ACID-CONTAINING CELLULAR-CONSTITUENTS - PROBES FOR MOLECULAR-BIOLOGY AND AUTOIMMUNE-DISEASE
复制标题

DOI:
10.1073/pnas.78.5.2737
复制
发表时间:
1981-01-01
期刊:
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES
影响因子:
--
通讯作者:
STEITZ, JA
STEITZ, JA
中科院分区:
其他
文献类型:
--
作者:
LERNER, EA;LERNER, MR;STEITZ, JA

文献摘要

被引文献

相似文献

MRL/Mp-lpr/lpr品系的小鼠发展成狼疮样综合征,其包括产生对含核酸的细胞组分特异性的自身抗体。我们将这种小鼠的脾细胞与骨髓瘤SP 2/0融合,并通过免疫沉淀和免疫荧光技术检测所得到的克隆杂交细胞系产生的抗体。目前已鉴定出三种单克隆抗体,分别对Sm、DNA或rRNA具有特异性,狼疮患者对这些抗原都产生抗体。以前曾报道患者抗Sm抗体沉淀五个小核核糖核蛋白,包含U-1,U-2,U-4,U-5和U-6 RNA。单克隆抗Sm抗体给出了相同的免疫沉淀模式,提供了直接的证据表明,Sm抗原驻留在所有这些RNA-蛋白质复合物。抗Sm单克隆抗体的建立将有助于阐明这些核内小核蛋白的生物学功能。一个简单的竞争放射免疫分析使用单克隆抗Sm抗体滴度患者血清。使用单克隆抗体的自身免疫性疾病的研究进行了讨论。
Mice of the strain MRL/Mp-lpr/lpr develop a lupus erythematosus-like syndrome that includes the production of autoantibodies specific for nucleic acid-containing cellular components. We have fused spleen cells from such a mouse with the myeloma SP 2/0 and examined the antibodies produced by the resultant cloned hybrid cell lines by using immunoprecipitation and immunofluorescence techniques. Three types of monoclonal antibodies, specific for Sm, DNA, or rRNA, all antigens to which patients who have lupus make antibodies, have been identified. Patient anti-Sm antibody had previously been reported to precipitate five small nuclear ribonucleoproteins that contain U-1, U-2, U-4, U-5, and U-6 RNAs. The monoclonal anti-Sm antibody gives the same immunoprecipitation pattern, providing direct evidence that the Sm antigen resides on all these RNA-protein complexes. Monoclonal anti-Sm antibody will be valuable in deciphering the biological function of these ubiquitous small nuclear RNPs. A simple competition radioimmunoassay using the monoclonal anti-Sm antibody to titer patient sera is also presented. Uses of monoclonal antibodies for the study of autoimmune disease are discussed.